Clopidogrel treatment for Silent Brain Infarction

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Silent Brain Infarction+2 More
Clopidogrel treatment - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether the drug clopidogrel can decrease the rate of new silent brain infarctions, which are linked to an increased risk for subsequent stroke and cognitive decline.

Eligible Conditions
  • Silent Brain Infarction

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 24 months

24 months
cognitive impairment
new silent brain infarctions

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Clopidogrel
1 of 2
Aspirin
1 of 2

Experimental Treatment

152 Total Participants · 2 Treatment Groups

Primary Treatment: Clopidogrel treatment · No Placebo Group · Phase 4

Clopidogrel
Drug
Experimental Group · 1 Intervention: Clopidogrel treatment · Intervention Types: Drug
Aspirin
Drug
Experimental Group · 1 Intervention: Aspirin treatment · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 24 months

Who is running the clinical trial?

VA Office of Research and DevelopmentLead Sponsor
1,474 Previous Clinical Trials
2,741,542 Total Patients Enrolled
Calin Ioan Prodan, MDPrincipal InvestigatorOklahoma City VA Medical Center, Oklahoma City, OK

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have symptoms for less than 96 hours.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 27th, 2021

Last Reviewed: November 17th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.